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Abstract
Background: Evidence suggests that folate deficiency may be causatively linked to depressive symptoms.
However, little is known on the status of use of folic acid and vitamin supplements among people with mental
disorders. This study examined the prevalence and the likelihood of use of folic acid or vitamin supplements
among adults with depression and anxiety in comparison to those without these conditions.
Methods: Using data from 46, 119 participants (aged ≥ 18 years) in the 2006 Behavioral Risk Factor Surveillance
System survey, we estimated the adjusted prevalence and odds ratios with 95% confidence intervals for taking folic
acid and vitamin supplements among those with ever diagnosed depression (n = 8, 019), ever diagnosed anxiety
(n = 5, 546) or elevated depressive symptoms (n = 3, 978, defined as having a depression severity score of ≥ 10 on
the Patient Health Questionnaire-8 diagnostic algorithm).
Results: Overall, women were more likely than men to take folic acid supplements 1-4 times/day (50.2% versus
38.7%, P < 0.001) and vitamin supplements (62.5% versus 49.8%, P < 0.001). After multivariate adjustment, men
with ever diagnosed depression or anxiety were 42% and 83%, respectively, more likely to take folic acid
supplements < 1 time/day; 44% and 39%, respectively, more likely to take folic acid supplements 1-4 times/day;
and 40% and 46%, respectively, more likely to take vitamin supplements compared to men without these
conditions (P < 0.05 for all comparisons). Women with ever diagnosed depression were 13% more likely to take
folic acid supplements 1-4 times/day and 15% more likely to take vitamin supplements than women without this
condition (P < 0.05 for both comparisons). Use of folic acid and vitamin supplements did not differ significantly by
elevated depressive symptoms in either sex.
Conclusion: The prevalence and the likelihood of taking folic acid and vitamin supplements varied substantially by
a history of diagnosed depression among both men and women and by a history of diagnosed anxiety among
men, but not by presence of elevated depressive symptoms in either sex.
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Background
Depression is recognized as an important cause of disabil-
ity and mortality worldwide [1,2]. Data from a population-
based survey in the United States showed that, in 2006,
approximately 15.4% of adults aged ≥ 18 years reported a
history of diagnosed depression, 8.4% reported having
moderate-to-severe depressive symptoms in the previous 2
weeks, and 11.0% reported a history of diagnosed anxiety
[3]. The burden of depression and other mental disorders
in the United States is substantial and associated with a
cost of $150 billion each year [4].
Evidence suggests that folate deficiency is causatively
linked to depressive symptoms because folate plays an
important role in the one-carbon metabolic pathway
involved in methylation processes and the synthesis of
neurotransmitters in the central nervous system [5,6].
Elevated homocysteine levels, a marker of folate deficiency
as well as vitamin B12 deficiency, can also cause oxidative
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damage and neurotransmitter deficiency [7,8]. To date,
majority of cross-sectional studies, several prospective
studies, and meta-analyses have shown that low levels of
serum or red blood cell folate, low levels of serum vitamin
B12, low dietary intake of folate and vitamin B12, and high
levels of serum homocysteine are associated with an
increased risk for depression [9-28]. Low folate levels have
also been associated with severe depressive disorders and
longer duration of depressive episodes [29]. In addition,
depressed people with low serum folate levels are signifi-
cantly less likely to respond to some antidepressant medi-
cations (such as fluoxetine) [30-32] and more likely to
relapse during treatment [33]. In contrast, higher intakes
of folate, vitamins B6 and B12 have been shown to be pro-
tective of depressive symptoms in some studies [34-36],
but not in others [37].
The National Health and Nutrition Examination Survey
(NHANES) data from 1999-2000 showed that 52% of U.S.
adults reported taking dietary supplements in the previous
month and that 35% reported use of multivitamin-multi-
mineral supplements [38]. However, the status of use of
folic acid and vitamin supplements among people with
depression is unknown. We hypothesized that use of these
supplements may be positively associated with previously
diagnosed depression; the currently elevated depressive
symptoms may be inversely related to use of these supple-
ments. To shed light on these questions, we examined the
prevalence and the likelihood of taking folic acid and vita-
min supplements among adults with depressive disorders
in comparison with those without these conditions by
using data from a population-based survey sample. In
addition, because depression and anxiety often coexist in
people with mental disorders [39], we also examined the
prevalence and the likelihood of taking folic acid and
vitamin supplements among adults with or without ever
diagnosed anxiety, although associations of folate and
B-vitamins with anxiety remain to be elucidated.
Methods
Survey design, participants, and data
Data for our analyses came from the Behavioral Risk
Factor Surveillance System (BRFSS), a population-based
telephone survey of health-related behaviors regarding
the leading causes of death among noninstitutionalized
U.S. adults aged ≥ 18 years. The BRFSS is considered to
be exempt from review by the Institutional Review Board
of the Centers for Disease Control and Prevention. The
BRFSS survey design, sampling methods and weights
have been described elsewhere [40], and BRFSS data have
consistently been found to provide valid and reliable esti-
mates when compared with data from other national
household surveys in the United States [40-42]. Further
information on the BRFSS is available at http://www.cdc.
gov/brfss/.
We analyzed the data collected from survey participants
in 9 states (Delaware, Florida,G e o r g i a ,M i n n e s o t a ,M i s -
souri, Montana, Virginia, Wisconsin, and Wyoming) and
Puerto Rico that had optional modules on folic acid and
vitamin supplementation and on anxiety and depression in
the 2006 BRFSS. The median cooperation rate (the per-
centage of eligible persons contacted who completed the
interview) for the 2006 BRFSS was 74.5%.
Use of vitamin supplements was assessed by asking par-
ticipants whether they were currently taking any vitamin
pills or supplements and their response to the question
was dichotomized as yes/no. The use of folic acid supple-
ments was assessed by asking participants whether they
were taking folic acid supplements or taking multivitamins
or any vitamin pills/supplements that contained folic acid
and, if so, how many times a day they were taking such
supplements. Their responses to the question were cate-
gorized as 1) not taking folic acid supplements, 2) taking
folic acid supplements < 1 time/day, and 3) taking folic
acid supplements 1-4 times/day. Those who answered that
they were taking folic acid supplements > 4 times/day
were excluded from the analyses because fewer than 0.5%
of participants were in this category. Self-reports of vita-
min and mineral supplement use have been reported to
have high reliability and validity [43].
Participants’ mental health status was assessed by asking
them whether they had ever been told by a doctor or
other healthcare provider that they had a depressive disor-
der (including depression, major or minor depression, or
dysthymia) or an anxiety disorder (including acute or post-
traumatic stress disorder, anxiety, generalized anxiety dis-
order, obsessive-compulsive disorder, panic disorder,
phobia, or social anxiety disorder). Those who answered
“yes” to either question were defined as having ever diag-
nosed depression or anxiety. Participants’ current depres-
sive symptoms were assessed using the Patient Health
Questionnaire-8 (PHQ-8) diagnostic algorithm, which has
been described in detail elsewhere [3,44,45]. Specifically,
participants were asked about how many days in the pre-
vious 2 weeks they experienced each of the following
symptoms of depression: 1) little interest or pleasure in
doing things; 2) feeling down, depressed, or hopeless; 3)
having trouble falling asleep or staying asleep or sleeping
too much; 4) feeling tired or little energy; 5) having a poor
appetite or eating too much; 6) feeling bad as a failure or
letting themselves or their family down; 7) having trouble
concentrating on things such as reading the newspaper or
watching the TV; and 8) moving or speaking too slowly or
being so fidgety or restless that they were moving around
a lot more than usual. For each item, respondents scored
as 0 point for 0-1 day with reported symptoms, 1 point for
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days. Their scores for each item were then added to
produce a total depression severity score, and those with a
total depression severity score of ≥ 10 were defined as hav-
ing elevated depressive symptoms (EDS). The PHQ-8 has
been shown to provide valid measurements on major
depression in the general population similar to that of the
PHQ-9 (which includes the ninth question about thoughts
of suicidality or self-injury) [46-49], and the scoring of ≥
10 on the PHQ-8 has been shown to have a sensitivity and
specificity of 88% for major depression [47]. Currently, the
reliability or validity of the measures for physician diagno-
sis of depression and anxiety in the BRFSS has not been
determined due to lack of research. However, in psychia-
tric epidemiology, lifetime prevalence, estimated as the
proportion of a sample having had at least one episode of
mental disorders in their life prior to the survey, is one of
the most commonly used parameters to assess history of
mental disorders [3,39,44,45]. This measure reflects a view
that most mental disorders are chronic conditions and
symptomatic episodes of mental disorders are often inter-
spersed with periods of remission.
The demographic variables in our analyses included
respondents’ age, sex, race/ethnicity (non-Hispanic white,
non-Hispanic black, Hispanic, or other), education (<
high school diploma, high school graduate, some college
or technical school, or ≥ college graduate), marital status
(married, divorced, never married, or other), and body
mass index (BMI, self-reported weight divided by height
in square). Respondents’ smoking status was categorized
as current smokers (participants who had smoked ≥ 100
cigarettes during their lifetime and were still smoking),
former smokers (those who had smoked ≥ 100 cigarettes
in their entire life but had stopped smoking), and never
smokers (those who had never smoked or smoked < 100
cigarettes during their lifetime). Leisure-time physical
activity was assessed by asking respondents whether, dur-
ing the previous month, they had participated in any phy-
sical activities or exercise other than their regular job.
Heavy alcohol drinking was defined as women who had
> 1 drink/day or men who had > 2 drinks/day during the
previous 12 months.
Statistical analyses
Of a total of 55, 867 survey participants, after excluding
from the analyses participants who responded “don’t
know/not sure, “refused to answer, or had missing
responses for any of the questions described above, 46,
119 participants remained in our analyses. We estimated
the adjusted prevalence of taking folic acid and vitamin
supplements in adult men and women. We tested the
interactive effects of sex with all three mental disorders
on the outcome measurements (i.e., use of folic acid and
vitamin supplements) in the fully adjusted models which
included the main effects of sex and mental disorders.
The interaction terms were significant so we conducted
sex-stratified analysis. Adjusted prevalence (predicted
marginal probability) of taking folic acid and vitamin
supplements was estimated by conducting logistic
regression analyses after adjustment for age, race/ethni-
city, education, body mass index, marital status, smoking
status, leisure-time physical activity, and heavy alcohol
drinking. We also estimated the adjusted odds ratios
(AORs) with 95% confidence intervals (CIs) for taking
folic acid and vitamin supplements using mental disor-
ders as exposure variables while controlling for demo-
graphic variables and lifestyle factors as listed above. We
used SUDAAN, 9.0 (Research Triangle Institute,
Research Triangle Park, NC) to account for the multi-
stage, disproportionate stratified sampling design.
Results
Of the 46, 119 participants, the age-adjusted prevalence of
ever diagnosed depression was 15.0% [men-10.4% versus
women-19.4% (P < 0.001)], the age-adjusted prevalence of
ever diagnosed anxiety was 11.2% [men-8.2% versus
women-14.1% (P < 0.001)], and the age-adjusted preva-
lence of EDS was 8.3% [men-6.5% versus women-10.0%
(P < 0.001)]. The mean age of participants was 45.8 years,
and the mean BMI was 27.1 kg/m
2. Approximately 49.2%
of participants were men, 61.6% were married, and 34.6%
had an education of ≥ college graduate. By race/ethnicity,
70.9% were non-Hispanic white, 9.5% were non-Hispanic
black, 14.7% were Hispanic, and 4.9% were of “other” race/
ethnicity.
Participants with any of the three categories of mental
disorder were significantly younger than those without
(P < 0.001 for all) (Table 1). The weighted percentages
of participants who were male, married, or ≥ college
graduates were significantly lower (P < 0.01 for all), and
the weighted percentages of adults who were obese were
significantly higher (P < 0.001), among those with men-
tal disorders than among those without these conditions
(Table 1).
Overall, after multivariate adjustment for age, race/eth-
nicity, education, marital status, BMI, smoking status, lei-
sure-time physical activity, and heavy alcohol drinking,
women had a significantly higher prevalence of taking folic
acid supplements 1-4 times/day (50.2% versus 38.7%, P <
0.001; AOR:1.74, 95% CI:1.63-1.86) or taking vitamin sup-
plements (62.5% versus 49.8%, P < 0.001; AOR:1.76, 96%
CI:1.64-1.89) than men. In our logistic regression models,
we stratified data analyses by sex because of the significant
interactive effects of sex and mental disorders on the out-
come measurements. Compared with men without diag-
nosed depression and anxiety, those with a history of these
diagnoses had a significantly higher prevalence of taking
folic acid supplements 1-4 times/day, and significantly
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levels (< 1 time/day or 1-4 times/day) (P < 0.05 or P <
0.001, Table 2). Women with ever diagnosed depression
were also significantly more likely than women without
this condition to take folic acid supplements 1-4 times/day
(52.7% versus 49.8%, P < 0.05; AOR: 1.13, 95% CI: 1.02-
1.26). Similarly, men with ever diagnosed depression
(56.5% versus 48.8%, P < 0.001; AOR: 1.40, 95% CI: 1.18-
1.66) or anxiety (57.5% versus 49.0%, P < 0.001; AOR:
1.46, 95% CI: 1.18-1.80) and women with ever diagnosed
depression (65.0% versus 62.0%, P < 0.01; AOR: 1.15, 95%
CI: 1.04-1.28) were significantly more likely to report tak-
ing vitamin supplements than those who had never been
diagnosed with these conditions after adjustment for mul-
tiple demographic variables and lifestyle factors (Table 3).
No significant associations of EDS with taking folic acid
and vitamin supplements were observed in either sex
(Table 2 and Table 3).
For depression status, people who were ever diagnosed
with depression may or may not have EDS currently –this
may have affected their behaviors of taking dietary supple-
ments. Thus, we conducted further stratified analysis by
ever diagnosed depression and/or EDS. A total of 5, 657
participants [the age-adjusted prevalence: total-10.6%;
men-7.4% versus women-13.6% (P < 0.001)] reported
having ever diagnosed depression only, 1, 616 [the age-
adjusted prevalence: total-3.9%; men-3.4% versus women-
4.3% (P < 0.05)] reported having EDS only, and 2, 362 [the
age-adjusted prevalence: total-4.4%; men-3.1% versus
women-5.6% (P < 0.001)] reported having both. Compared
with men having neither ever diagnosed nor EDS, those
with ever diagnosed depression, regardless whether they
had EDS currently, were significantly more likely to take
folic acid supplements 1-4 times/day (AOR: 1.48, 95% CI:
1.22-1.81 for those with ever diagnosed depression only
and AOR: 1.31, 95% CI: 0.99-1.80 for those with both ever
diagnosed depression and EDS) and to take vitamin sup-
plements (AOR: 1.40, 95% CI: 1.16-1.69 for those with
ever diagnosed depression only and AOR: 1.39, 95% CI:
1.00-1.92 for those with both ever diagnosed depression
and EDS) (Figure 1 and Figure 2). Women with ever diag-
nosed depression but without EDS were also significantly
more likely to take folic acid supplements 1-4 times/day
(AOR: 1.13, 95% CI: 1.01-1.28) and to take vitamin supple-
ments (AOR: 1.20, 95% CI: 1.06-1.36) than were women
with neither conditions (Figure 1 and Figure 2); however,
Table 1 Demographic characteristics of study population (N = 46, 119) by depression and anxiety status, BRFSS, 2006*
Ever diagnosed depression Ever diagnosed anxiety EDS
yes no yes no yes no
n = 8, 019 n = 38, 100 n = 5, 546 n = 40, 573 n = 3, 978 n = 42, 141
Age (years) 44.4 (0.3) 46.0 (0.2) 43.7 (0.4) 46.0 (0.2) 42.0 (0.5) 46.1 (0.2)
Sex
Men 34.4 (1.0) 51.8 (0.4) 36.1 (1.2) 50.9 (0.4) 38.8 (1.6) 50.2 (0.4)
Women 65.6 (1.0) 48.2 (0.4) 63.9 (1.2) 49.1 (0.4) 61.2 (1.6) 49.8 (0.4)
Race/ethnicity
Non-Hispanic white 75.1 (0.8) 70.2 (0.4) 72.0 (1.0) 70.8 (0.4) 64.4 (1.5) 71.5 (0.4)
Non-Hispanic black 6.8 (0.6) 10.0 (0.3) 7.2 (0.7) 9.8 (0.3) 11.5 (1.0) 9.3 (0.2)
Hispanic 13.4 (0.6) 14.9 (0.3) 15.5 (0.8) 14.6 (0.3) 18.0 (1.2) 14.4 (0.3)
Others 4.8 (0.4) 4.9 (0.2) 5.2 (0.5) 4.8 (0.2) 6.1 (0.7) 4.8 (0.2)
Education
< high school diploma 11.4 (0.7) 9.2 (0.2) 13.0 (0.8) 9.1 (0.2) 21.1 (1.3) 8.5 (0.2)
High school graduate 29.1 (0.9) 28.1 (0.4) 28.8 (1.1) 28.2 (0.4) 33.5 (1.4) 27.8 (0.4)
Some college/technical 29.4 (0.9) 27.3 (0.4) 29.2 (1.1) 27.4 (0.4) 27.9 (1.4) 27.6 (0.4)
≥ College graduate 30.1 (0.9) 35.4 (0.4) 29.0 (1.0) 35.3 (0.4) 17.5 (1.1) 36.1 (0.4)
Body mass index (kg/m
2)
< 25.0 36.1 (1.0) 38.7 (0.4) 37.7 (1.2) 38.4 (0.4) 34.7 (1.5) 38.6 (0.4)
25.0- < 30.0 31.7 (0.9) 37.7 (0.4) 33.1 (1.1) 37.2 (0.4) 29.5 (1.4) 37.4 (0.4)
≥ 30.0 32.2 (0.9) 23.7 (0.4) 29.2 (1.0) 24.4 (0.4) 35.8 (1.3) 24.0 (0.3)
Marital status
Married 50.7 (1.0) 63.5 (0.4) 51.0 (1.2) 62.9 (0.4) 42.4 (1.4) 63.3 (0.4)
Divorced 15.0 (0.6) 8.0 (0.2) 14.1 (0.6) 8.4 (0.2) 14.8 (0.8) 8.5 (0.2)
Never married 18.4 (1.0) 17.4 (0.4) 20.2 (1.2) 17.2 (0.4) 23.0 (1.6) 17.1 (0.4)
Others 15.8 (0.7) 11.1 (0.2) 14.7 (0.8) 11.5 (0.2) 19.8 (1.3) 11.1 (0.2)
* Data presented as weighted percentages with standard errors in parentheses except for mean age. BRFSS = Behavioral Risk Factor Surveillance System, EDS =
Elevated depressive symptoms
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both ever diagnosed depression and EDS.
Discussion
Our results showed that, among participants from 9
states and 1 territory of the United States, use of folic
acid supplements 1-4 times/day (50.2% versus 38.7%) and
use of vitamin supplements (62.5% versus 49.8%) were
significantly higher among women than among men.
Men with ever diagnosed depression were more likely to
report taking folic acid and vitamin supplements than
men with no history of diagnosed depression regardless
whether they had elevated depressive symptoms. In con-
trast, although women with ever diagnosed depression
were significantly more likely to report taking folic acid
1-4 times/day and vitamin supplements than were
women with no history of diagnosed depression, these
differences were no longer statistically significant when
the status on elevated depressive symptoms was taken
into consideration.
To date, most previous studies have mainly focused on
the causal relationship between folate and mental disor-
ders. The results of these studies suggest that folate or
folinic acid (5-methyltetrahydrofolate) may serve as a
stand-alone treatment of depression [50,51] or an aug-
mentation of antidepressant treatment showing a signifi-
cant beneficial effect in reducing Hamilton Depression
Rating Scale Score when used with other psychotropic
medication [52-57]. Limited evidence from the Vitamins
and Lifestyle (VITAL) study showed that 10.4% of partici-
pants with depression who were taking medications for
depression reported taking dietary supplements and that
6.7% of those who felt depressed or anxious but did not
take medication for depression reported doing so [58]. In
that study, participants were limited to the 50 to 75 years
of age, and dietary supplements were a combination of 17
supplements including folic acid and various other vita-
mins. To our knowledge, our study is the first population-
based study to focus on the behaviors of use of folic acid
and vitamin supplements among adults with depression or
anxiety. Although our results showed that men with ever
diagnosed depression or anxiety and women with ever
diagnosed depression were more likely than those without
a history of these conditions to report taking folic acid
supplements (1-4 times/day), only about 50% of them
were doing so. Most importantly, we found that adults
Table 2 Adjusted prevalence (with standard error) of and adjusted odds ratios (with 95% confidence intervals) for
taking folic acid supplements among adults aged ≥ 18 years, by sex and by depression and anxiety status, BRFSS,
2006
Adjusted prevalence* Adjusted odds ratio*
Taking supplements No supplements Taking supplements
(times/day) < 1 1 to 4 < 1 1 to 4
% (SE) % (SE) % (SE) AOR 95% CI AOR 95% CI
Men (n = 18, 092)
Ever diagnosed depression
Yes (n = 2, 140) 7.6 (1.1) 45.1 (1.8)¶ 47.3 (1.9)¶ 1.42 1.00-2.00 1.44 1.21-1.71
No (n = 15, 952) 6.4 (0.4) 38.0 (0.6) 55.6 (0.6) 1.00 1.00
Ever diagnosed anxiety
Yes (n = 1, 508) 9.6 (1.8)† 43.6 (2.2)‡ 46.8 (2.3)¶ 1.83 1.18-2.84 1.39 1.13-1.70
No (n = 16, 584) 6.3 (0.4) 38.3 (0.6) 55.4 (0.6) 1.00 1.00
EDS
Yes (n = 1, 162) 10.6 (2.7) 37.5 (2.4) 52.0 (3.1) 1.79 0.96-3.34 1.02 0.80-1.30
No (n = 16, 930) 6.3 (0.4) 38.8 (0.6) 54.9 (0.6) 1.00 1.00
Women (n = 28, 027)
Ever diagnosed depression
Yes (n = 5, 879) 6.6 (0.6) 52.7 (1.1)‡ 40.7 (1.0)‡ 0.97 0.76-1.24 1.13 1.02-1.26
No (n = 22, 148) 7.2 (0.3) 49.8 (0.5) 43.0 (0.5) 1.00 1.00
Ever diagnosed anxiety
Yes (n = 4, 038) 7.0 (0.8) 51.8 (1.3) 41.3 (1.2) 1.02 0.78-1.33 1.08 0.96-1.22
No (n = 23, 989) 7.1 (0.3) 50.1 (0.5) 42.8 (0.5) 1.00 1.00
EDS
Yes (n = 2, 816) 7.5 (1.2) 49.2 (1.6) 43.2 (1.5) 1.05 0.73-1.51 0.96 0.83-1.10
No (n = 25, 211) 7.0 (0.3) 50.5 (0.5) 42.5 (0.5) 1.00 1.00
*Adjusted for age, race/ethnicity, education, body mass index, marital status, smoking, leisure-time exercise, and alcohol consumption. †P = 0.065, ‡P < 0.05, and
¶P < 0.001 for comparisons between adults with ever diagnosed depression or anxiety and those without. AOR = Adjusted odds ratio, BRFSS = Behavioral Risk
Factor Surveillance System, CI = Confidence interval, EDS = Elevated depressive symptoms, SE = Standard error
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those without these symptoms to report taking folic acid
supplements. At present, studies have consistently
reported a high prevalence of depressive symptoms in
populations [3,45,59], and these symptoms are strongly
associated with first-onset major depression [59]. In addi-
tion, most depressive symptoms are often unrecognized
and untreated in clinical practice. Given the links between
folate deficiency and depressive symptoms [9-28], the use
of folic acid supplements may possibly prevent or delay
the onset of major depression among people with elevated
depressive symptoms, although randomized trials are
needed to confirm it.
Other than folate, studies have shown that low levels of
vitamin B6 and B12 were also related to depressive disor-
ders [16,19,23,26,27,60-62], however, other studies failed
to show any relationship between vitamin B12 and depres-
sive symptoms [12,20,25,30]. Similarly, high intakes of
vitamins B6 and B12 have shown to be protective of
depressive symptoms in a prospective study [36], but not
in others [34,37]. Thus, the controversial results remained
to be elucidated in the future. Nonetheless, B-vitamins
including B6 and B12 have known to be important for
essential functioning of the one-carbon metabolism in the
biosynthesis of monoamine neurotransmitters including
serotonin, dopamine, norepinephrine, and epinephrine
[60-62], all of which are known to affect mood and cogni-
tion. Our results showed that, although adults with ever
d i a g n o s e dd e p r e s s i o nw e r es i g n i f i c a n t l ym o r el i k e l yt o
report taking vitamin supplements than those with no his-
tory of diagnosed depression, only less than two-thirds of
them reported taking vitamin supplements. Taken
together, our results call for further research or clinical
trials that may help to establish whether the use of folic
acid and vitamin supplements should be improved among
people with mental disorders.
Our results further demonstrated that men with ever
diagnosed anxiety were significantly more likely to report
taking folic acid and vitamin supplements, although these
relationships were not observed among women with
anxiety. At present, the relationship between anxiety and
use of folic acid and vitamin supplementats is unknown.
However, given the high prevalence of anxiety in the U.S.
population [3,45] and its coexistence with depression
[39], further investigation of the role of folic acid and
vitamin supplementation in the prevention and treatment
of anxiety is needed.
There are several limitations in the present study. First,
all data were based on the self-reports by survey partici-
pants and thus subject to recall bias. Second, the infor-
mation on the severity and diagnosis date of mental
disorders was not available in the BRFSS. Third, given
Table 3 Adjusted prevalence (with standard error) of and adjusted odds ratios (with 95% confidence intervals) for
taking vitamin supplements among adults aged ≥ 18 years, by sex and by depression and anxiety status, BRFSS, 2006
Adjusted prevalence* Adjusted odds ratio*
% (SE) AOR 95% CI
Men (n = 18, 497)
Ever diagnosed depression
Yes (n = 2, 140) 56.5 (1.8)¶ 1.40 1.18-1.66
No (n = 15, 952) 48.8 (0.6) 1.00
Ever diagnosed anxiety
Yes (n = 1, 508) 57.5 (2.3)¶ 1.46 1.18-1.80
No (n = 16, 584) 49.0 (0.6) 1.00
EDS
Yes (n = 1, 162) 52.1 (3.1) 1.12 0.86-1.47
No (n = 16, 930) 49.5 (0.6) 1.00
Women (n = 28, 332)
Ever diagnosed depression
Yes (n = 5, 879) 65.0 (1.0)§ 1.15 1.04-1.28
No (n = 22, 148) 62.0 (0.5) 1.00
Ever diagnosed anxiety
Yes (n = 4, 038) 64.0 (1.2) 1.08 0.95-1.22
No (n = 23, 989) 62.4 (0.5) 1.00
EDS
Yes (n = 2, 816) 61.2 (1.5) 0.92 0.80-1.07
No (n = 25, 211) 62.8 (0.5) 1.00
*Adjusted for age, race/ethnicity, education, body mass index, marital status, smoking, leisure-time physical activity, and alcohol consumption. § P < 0.01, ¶ P <
0.001 for comparisons between adults with ever diagnosed depression or anxiety and those without. AOR = Adjusted odds ratio, BRFSS = Behavioral Risk Factor
Surveillance System, CI = Confidence interval, EDS = Elevated depressive symptoms, SE = Standard Error
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Page 6 of 10the cross-sectional nature of the survey, the temporal
relationship between the use of folic acid and vitamin
supplements and the presence of depression, anxiety, or
elevated depressive symptoms cannot be established in
the present study. Evidence suggests that folate/vitamin
deficiency may affect one-carbon metabolic pathway and
neurotransmitter synthesis in the central nervous system,
thereby linking to depressive disorders. On the other
hand, people who are diagnosed with mental disorders
m a yb em o r el i k e l yt ot a k ed i e t a r ys u p p l e m e n t s .T h u s ,
bidirectional associations may exist. Fourth, although we
have assessed the frequency of folic acid supplementa-
tion, the amount of daily folic acid and vitamin intake as
well as the biomarkers of folic acid and vitamin supple-
mentation (i.e., serum or red blood cell folate levels,
serum homocysteine levels, or serum vitamin levels) was
unknown in the present study. Also, data on dietary
intake of folate and vitamins as well as dietary energy
intake were not available in the BRFSS so we were unable
to assess whether these variables may have confounding
effects. Fifth, women of reproductive age may be more
likely to take folic acid and vitamin supplements. In addi-
tion, people with chronic conditions such as cardiovascu-
lar disease and diabetes may confer higher risks for
depression. Thus, further stratified analysis in women of
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(n=15,407)       (n=545)          (n=1,523)         (n=617)
(n=21,077)      (n=1,071)        (n=4,134)       (n=1,745)
Figure 1 Adjusted odds ratios (with 95% confidence intervals) for taking folic acid supplements 1-4 times/day among men (top) and
women (bottom) aged ≥ 18 years with either ever diagnosed depression or elevated depressive symptoms (EDS) or both.
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Page 7 of 10warranted in future studies. Finally, use of prescribed
medications (including prescribed folate or other supple-
ments that contain folate) for depression, anxiety, or
other mental disorders was not ascertained, thus, we
were unable to conduct stratified analyses by medication
use.
Conclusions
Our results from a large, nationally representative sam-
ple demonstrated that substantial variations exist in the
prevalence and the likelihood of taking folic acid and
vitamin supplements by sex and by histories of pre-
viously diagnosed depression and anxiety, but not by
presence of elevated depressive symptoms. Our results
provide fundamental information on the status of
dietary supplement use among U.S. adults with mental
disorders, and have important implications in public
health nutrition given that high intakes of folic acid and
vitamins may reduce the risk for depressive disorders
[34-36] and increase medication response in depressed
patients [52-57].
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